GRAL - Wutah pendapatan taunan sajrone rolas wulan kepungkur GRAIL, Inc.

Logo grafis GRAIL Bio (GRAL)

Analyzing the chart on GURU.Markets, the LTM sales growth YoY for GRAIL, Inc. (GRAL) stands at 17.80, driven by Galleri test sales to individuals and clinics. However, GRAIL, Inc. (GRAL) is burning capital due to costly research, resulting in deeply negative FCF. The company's future success depends on regulatory approval and the expansion of insurance reimbursements under strict liquidity control.

Wutah dodolan YoY (TTM): GRAIL (GRAL) kanggo 23.11.2025 - 17.11.2026

grail.com (GRAL) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
Ringkesan analitik perusahaan:GRAL GRAIL Bio
Produk merek GRAIL, Inc.

This indicator determines investment reliability via a daily calculation of rolling year revenue growth, identifying real business expansion regardless of seasonal fluctuations. By analyzing the 12-month year-over-year revenue dynamics, an investor assesses the scalability of high-tech sequencing and AI implementation in oncology diagnostics for GRAIL, Inc. (GRAL), where process robotization must convert into sustainable financial growth.